stockrowRecursion Pharmaceuticals, Inc. (RXRX) vs Zymeworks Inc. (ZYME)
- Recursion Pharmaceuticals, Inc. RXRX 3.57 +0.56%
- Zymeworks Inc. ZYME 29.08 −7.57%
Recursion Pharmaceuticals, Inc. and Zymeworks Inc. are both Biotechnology companies. Recursion Pharmaceuticals, Inc. and Zymeworks Inc. are of similar size ($2.2B and $2.2B). Recursion Pharmaceuticals, Inc. has negative trailing earnings, so its P/E is not meaningful; Zymeworks Inc. trades at 43.7×. Zymeworks Inc. grew revenue faster over the last twelve months: 97.8% against 56.2%. Zymeworks Inc. has the higher net margin (16.3% vs −697.1%) and the higher return on invested capital (17.5% vs −88.5%). Across the 18 metrics below, Zymeworks Inc. leads on 14 and Recursion Pharmaceuticals, Inc. on 4.
Valuation
Profitability
| Metric | RXRX | ZYME | Biotechnology median |
|---|---|---|---|
| Gross margin | 29.21% | 51.40% | 68.81% |
| Operating margin | (725.44%) | 16.60% | 0.00% |
| Net margin | (697.13%) | 16.28% | 0.00% |
| Free cash flow margin | (460.89%) | (42.42%) | 0.00% |
| Return on equity | (48.72%) | 14.98% | (50.30%) |
| Return on assets | (36.29%) | 5.50% | (45.47%) |
| Return on invested capital | (88.54%) | 17.49% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack